INGREZZA® (valbenazine) capsules by Neurocrine Biosciences, Inc. 


Physician Resources
3 FILES

Physician Resources
Access and Support
3 FILES

Access & Support
Resources for Your Patients
2 FILES

Patient Resources
Indications & Usage

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.


Please see INGREZZA full Prescribing Information

Dosage & Administration

• The initial dosage is 40 mg once daily.

• After the first week, 80 mg is recommended once daily, but 40 mg or 60 mg once daily may be considered based on individual treatment needs, response, and tolerability

• Can be taken any time of day with or without food.

• The recommended dosage for patients with moderate or severe hepatic impairment is 40 mg once daily.

• The recommended dosage for known CYP2D6 poor metabolizers is 40 mg once daily.

 

Capsules: 40 mg, 60 mg, and 80 mg.


Please see INGREZZA full Prescribing Information



© 2021 Neurocrine Biosciences, Inc. All Rights Reserved.

CP-VBZ-US-1584  08/2021

Sponsored and developed by Neurocrine Biosciences, Inc.



Please see INGREZZA full Prescribing Information


Indication and Important Safety Information


Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information